FDA Approves Onglyza (saxagliptin) for Type 2 Diabetes
Links shared publicly online about this topic.
- 1,856total visits
FDA Approves Onglyza (saxagliptin) for Type 2 Diabetes
View full resource at drugs.com
Tags: Diabetes, Diabetes Type 2 Medication, Type 2 Diabetes, FDA, Onglyza
Most Recently Shared on August 1, 2009 at 3:03 am By:
FDA Approves Onglyza (saxagliptin) for Type 2 Diabetes - http://bit.ly/19lKrd
European Commission approves ONGLYZA as combination therapy with insulin for type 2 diabetes
news-medical.net — “Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved ONGLYZA (saxagliptin) for use as a combination therapy with insulin (with or without metformin) to improve blood sugar (glycaemic) control in adult patients with type 2 diabetes.” View full resource at news-medical.net
Most Recently Shared on November 28, 2011 at 5:30 pm By:
European Commission approves ONGLYZA as combination therapy with insulin for type 2 diabetes: Bristol-Myers Squi... http://t.co/mO9KYHaO
European Commission approves ONGLYZA as combination therapy with insulin for type 2 diabetes
news-medical.net — “Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved ONGLYZA (saxagliptin) for use as a combination therapy with insulin (with or without metformin) to improve blood sugar (glycaemic) control in adult patients with type 2 diabetes.” View full resource at news-medical.net
Most Recently Shared on November 28, 2011 at 3:53 pm By:
Diabetes News: European Commission approves ONGLYZA as combination therapy with insulin for type 2 diabetes: Bri... http://t.co/IjDwRuPp
Onglyza Becomes The First DPP4 Inhibitor Available For Use In Europe In Type 2 Diabetes Patients With Moderate Or Severe Renal Impairment
medicalnewstoday.com — “AstraZeneca and Bristol-Myers Squibb Company announced that the European Commission has approved a label update for ONGLYZA® (saxagliptin) in the treatment of adults with type 2 diabetes who h” View full resource at medicalnewstoday.com
Most Recently Shared on March 5, 2011 at 4:39 pm By:
Urology & Nephrology OW Health
Onglyza Becomes The First DPP4 Inhibitor Available For Use In Europe In Type 2 Diabetes Patients With Moderate O... http://bit.ly/gf3nof
Onglyza Becomes The First DPP4 Inhibitor Available For Use In Europe In Type 2 Diabetes Patients With Moderate Or Severe Renal Impairment
medicalnewstoday.com — “AstraZeneca and Bristol-Myers Squibb Company announced that the European Commission has approved a label update for ONGLYZA® (saxagliptin) in the treatment of adults with type 2 diabetes who h” View full resource at medicalnewstoday.com
Most Recently Shared on March 5, 2011 at 10:05 am By:
Onglyza Becomes The First DPP4 Inhibitor Available For Use In Europe In Type 2 Diabetes Patients With Moderate Or Seve... http://mnt.to/3RW4
ONGLYZA™ (Saxagliptin) U.S. Label Update Provides Further Evidence Regarding Use In Renally Impaired Adults With Type 2 Diabetes
medicalnewstoday.com — “Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration has approved the inclusion of data from two clinical studies in an u” View full resource at medicalnewstoday.com
Most Recently Shared on February 25, 2011 at 4:05 pm By:
ONGLYZA™ (Saxagliptin) U.S. Label Update Provides Further Evidence Regarding Use In Renally Impaired Adults With... http://mnt.to/3RzL
FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies
news-medical.net — “Bristol-Myers Squibb Company, and AstraZeneca today announced that KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release), approved by the U.S. Food and Drug Administration (FDA) on November 5, 2010, is now available by prescription in pharmacies across the United States.” View full resource at news-medical.net
Most Recently Shared on January 7, 2011 at 5:01 pm By:
FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies: Bristol-Myers Squibb Compan... http://bit.ly/dLge7K
Kombiglyze XR tablets approved for the treatment of type 2 diabetes mellitus in adults - - Drug Topics
drugtopics.modernmedicine.com — “FDA has approved saxagliptin and metformin extended-release (XR) (Kombiglyze XR, AstraZeneca/Bristol-Myers Squibb) tablets for the treatment of type 2 diabetes in adults. Kombiglyze XR is the first and only once-a-day metformin XR plus dipeptidyl peptidase-4 (DPP-4) inhibitor combination tablet offering strong glycemic control across glycosylated hemoglobin levels, fasting plasma glucose, and postprandial glucose.” View full resource at drugtopics.modernmedicine.com
Most Recently Shared on November 12, 2010 at 2:02 pm By:
Kombiglyze XR tablets approved for the treatment of type 2 diabetes mellitus in adults: FDA has approved saxagli... http://bit.ly/cIZrir
Kombiglyze XR approved for treatment of type 2 diabetes mellitus (DM) - MPR
empr.com — “The FDA has approved Kombiglyze XR (saxagliptin and metformin, from Bristol-Myers Squibb and AstraZeneca) for the treatment of type 2 diabetes in adults.” View full resource at empr.com
Most Recently Shared on November 8, 2010 at 10:16 pm By:
MPR News: Kombiglyze XR approved for treatment of type 2 diabetes mellitus (DM): The FDA has approved Kombiglyze... http://bit.ly/dpvnIq
Kombiglyze™ Xr (Saxagliptin And Metformin Hcl Extended-Release) Tablets Approved In The U.S. For The Treatment Of Type 2 Diabetes Mellitus In Ad
medicalnewstoday.com — “Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) approved KOMBIGLYZE™ XR for the treatment of type 2 diabetes i” View full resource at medicalnewstoday.com
Most Recently Shared on November 8, 2010 at 6:05 pm By:
Kombiglyze™ Xr (Saxagliptin And Metformin Hcl Extended-Release) Tablets Approved In The U.S. For The Treatment O... http://mnt.to/3Mcv
FDA approves metformin/saxagliptin combination for type 2 diabetes
endocrinetoday.com — “The once-daily metformin extended-release plus dipeptidyl peptidase-4 tablet demonstrated significant reductions in HbA1c levels, fasting plasma” View full resource at endocrinetoday.com
Most Recently Shared on November 8, 2010 at 4:36 pm By:
#FDA approves metformin/saxagliptin combination for type 2 diabetes http://bit.ly/aJUY00
Kombiglyze XR (Saxagliptin and Metformin HCl Extended-Release) Tablets Approved in the U.S. for the Treatment of Type 2 Diabetes Mellitus in Adults
drugs.com — “Kombiglyze XR (saxagliptin and metformin) is used to treat type 2 diabetes. Includes Kombiglyze XR side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on November 7, 2010 at 9:55 pm By:
FDA Approves Kombiglyze XR (saxagliptin and metformin) for the Treatment of Type 2 Diabetes Mellitus - http://bit.ly/bGBTlz
KOMBIGLYZE" XR (Saxagliptin and Metformin HCl Extended-Release) Tablets Approved in the U.S. for the Treatment of Type 2 Diabetes Mellitus in Adults
businesswire.com — “Bristol-Myers Squibb and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved KOMBIGLYZE™ XR for the treatment” View full resource at businesswire.com
Most Recently Shared on November 6, 2010 at 5:28 pm By:
KOMBIGLYZEâ„¢ XR (Saxagliptin and Metformin HCl Extended-Release) Tablets Approved in the U.S. (BioSpace) http://bit.ly/c9ijsw
KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release) tablets approved in the U.S. for the treatment of type 2 diabetes mellitus in adults
astrazeneca-us.com — “Visit the AstraZeneca U.S. Corporate Web site (www.astrazeneca-us.com) for more information.” View full resource at astrazeneca-us.com
Most Recently Shared on November 5, 2010 at 5:21 pm By:
eyeonfda Pharma and Health Lawyer
AZ sez FDA approves KOMBIGLYZEâ„¢ XR (saxagliptin and metformin HCl extended-release) tablets for type 2 adult diabetes http://ow.ly/357wz
Diabetes Drugs: DPP-4 Inhibitors :: Diabetes Self-Management
diabetesselfmanagement.com — “Dpp-4 inhibitors, a relatively new class of drugs for type 2 diabetes, were introduced in 2006. sitagliptin (brand name januvia), the first medicine in this class, was approved for the treatment of type 2 diabetes in october 2006; in july 2009, a second dpp-4 inhibitor, saxagliptin (onglyza), was approved...” View full resource at diabetesselfmanagement.com
Most Recently Shared on October 2, 2009 at 8:06 pm By:
Diabetes Self-Mgmt Health Site
#diabetes The science behind this drug class has been developing for over 100 years. Learn more about it. http://bit.ly/LNDUp
DPP-4 Inhibitors :: Diabetes Self-Management
diabetesselfmanagement.com — “In 2006, a new class of medicine for Type 2 diabetes was introduced to the U.S. market. Called DPP-4 inhibitors, these drugs work in a way that is different from any previous diabetes treatment. Sitagliptin (brand name Januvia) is the first drug in this class to be approved; it can be used alone or in combination with other oral diabetes drugs. Saxagliptin (Onglyza), another DPP-4 inhibitor, received approval in August 2009...” View full resource at diabetesselfmanagement.com
Most Recently Shared on August 12, 2009 at 7:05 pm By:
Diabetes Self-Mgmt Health Site
#diabetes Article of the Week: DPP-4 Inhibitors: A Novel Class of Drugs for Type 2 Diabetes http://bit.ly/19Q8o8
Advertisement
